XM does not provide services to residents of the United States of America.
R
R

Roche

News

Roche Receives FDA Approval For First Molecular Test To Screen For Malaria In Blood Donors

BRIEF-Roche Receives FDA Approval For First Molecular Test To Screen For Malaria In Blood Donors March 26 (Reuters) - Roche Holding AG ROG.S : ROCHE RECEIVES FDA APPROVAL FOR THE FIRST MOLECULAR TEST TO SCREEN FOR MALARIA IN BLOOD DONORS COBAS MALARIA TEST IS FIRST FDA-APPROVED MOLECULAR TEST TO SCREEN U.S. BLOOD DONORS FOR MALARIA COBAS MALARIA TEST IS FIRST FDA-APPROVED MOLECULAR TEST TO SCREEN U.S.
R

US FDA grants full approval to AbbVie's ovarian cancer therapy

UPDATE 1-US FDA grants full approval to AbbVie's ovarian cancer therapy Adds details throughout March 22 (Reuters) - The U.S. Food and Drug Administration said on Friday it had granted traditional approval for AbbVie's ABBV.N "guided missile" cancer therapy, Elahere, for patients with a type of ovarian cancer. Elahere was approved for adult patients with a type of cancer which affects the ovaries, fallopian tube, or walls of the abdomen, and have received one to three prior lines of treatment, a
R

U.S. STOCKS Advance Auto Parts, Illumina, Reddit

BUZZ-U.S. STOCKS ON THE MOVE-Advance Auto Parts, Illumina, Reddit Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes touched record highs on Thursday as chip stocks rallied following Micron Technology's upbeat forecast, while investors took comfort in the Federal Reserve sticking to its three-rate-cut view for this year.
A
B
G
I
J
M
R
T
U
U
L
A
D

Immunovant and Argenx rise as rival Chugai's data fails to impress

BUZZ-Immunovant and Argenx rise as rival Chugai's data fails to impress ** Shares of Immunovant IMVT.O rise 2.5% to $32.36 and U.S.-listed shares of Argenx ARGX.O gain 12.3% to $401 after Japan-based Chugai Pharma 4519.T reported late-stage data of its autoimmune disease drug satralizumab ** Chugai said the drug did not "reach our expectations on t
R

Luxury stocks pressure European equities ahead of Fed verdict

UPDATE 2-Luxury stocks pressure European equities ahead of Fed verdict For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window STOXX 600 end flat Kering flags Q1 sales drop, top decliner on STOXX 600 Lonza to buy biologics site from Roche in US for $1.2 bln Johnson Matthey to sell medical device parts unit for $700 mln Updated at 1650 GMT By Khushi Singh and Amruta Khandekar March 20 (Reuters) - European shares were flat on Wednesday, pressured
B
B
C
K
L
L
R
R
S
J
E
F
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.